Actively Recruiting
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
Led by University of Illinois at Chicago · Updated on 2025-08-24
162
Participants Needed
4
Research Sites
286 weeks
Total Duration
On this page
Sponsors
U
University of Illinois at Chicago
Lead Sponsor
M
Medtronic
Collaborating Sponsor
AI-Summary
What this Trial Is About
In this pilot and feasibility study, the investigators will enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) in a cross-over study testing two different classes of anti arrhythmic drugs (AADs). This pilot and feasibility study will provide preliminary data for a larger study in which the investigators will test the hypothesis that a common AF genetic risk allele modulates response to different AADs.
CONDITIONS
Official Title
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- ≥ 18 years of age
- History of typical or early-onset symptomatic (≥2 episodes/month) paroxysmal/persistent AF
- ECG that was recorded within 1 month of randomization showing AF
- Eligible for both Flecainide(Class I) and Sotalol (Class III) AAD
- Able to give informed consent
You will not qualify if you...
- Permanent AF or isolated atrial flutter
- Cardiac or thoracic surgery within the previous 6 months
- Previous use of amiodarone other than short-term use (e.g. for an acute arrhythmia in hospital)
- Medical condition that is likely to be fatal in less than one year
- A history of prior AF ablation
- Have already been tried on 2 or more AADs in the past for AF
- Creatinine clearance <40 ml/min
- Left ventricular ejection fraction < 50%
- Contra-indication to a Class I AAD e.g., structural heart disease, or history of MI
- Contra-indication to a Class III AAD, e.g., congenital or acquired long QT syndrome with QTc>480 ms in females and >460 ms in males at baseline
- A reversible cause of AF (e.g., hyperthyroidism)
- Females who are pregnant or nursing
- History of severe AV node dysfunction unless an electronic pacemaker is present
- First- or second-degree relative has already participated in the study
- Unable to adhere to study procedures that are strictly for research purposes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Jesse Brown VA Medical Center
Chicago, Illinois, United States, 60612
Not Yet Recruiting
2
Rush University Medical Center
Chicago, Illinois, United States, 60612
Not Yet Recruiting
3
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
Actively Recruiting
4
Advocate Christ Medical Center
Oak Lawn, Illinois, United States, 60453
Not Yet Recruiting
Research Team
D
Dawood Darbar, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here